182 related articles for article (PubMed ID: 33708434)
1. High expression of aldolase A is associated with tumor progression and poor prognosis in hepatocellular carcinoma.
Tang Y; Yang X; Feng K; Hu C; Li S
J Gastrointest Oncol; 2021 Feb; 12(1):174-183. PubMed ID: 33708434
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of Stress-Induced Protein Kinase CK1 Delta is associated with a Poor Prognosis for patients with Hepatocellular Carcinoma.
Zhang H; Qiu C; Zeng H; Zhu W; Lyu W; Lao X
Genet Test Mol Biomarkers; 2021 Jul; 25(7):504-514. PubMed ID: 34280005
[No Abstract] [Full Text] [Related]
3. Overexpression of PARPBP Correlates with Tumor Progression and Poor Prognosis in Hepatocellular Carcinoma.
Yu B; Ding Y; Liao X; Wang C; Wang B; Chen X
Dig Dis Sci; 2019 Oct; 64(10):2878-2892. PubMed ID: 30949905
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of ERCC6L is associated with tumor progression and unfavorable prognosis in hepatocellular carcinoma.
Yu B; Liang H; Ye Q; Wang Y
J Gastrointest Oncol; 2020 Oct; 11(5):1009-1023. PubMed ID: 33209494
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Implications and Immune Infiltration Analysis of ALDOA in Lung Adenocarcinoma.
Lu G; Shi W; Zhang Y
Front Genet; 2021; 12():721021. PubMed ID: 34925439
[No Abstract] [Full Text] [Related]
6. Bioinformatics analysis of the role of aldolase A in tumor prognosis and immunity.
Tian W; Zhou J; Chen M; Qiu L; Li Y; Zhang W; Guo R; Lei N; Chang L
Sci Rep; 2022 Jul; 12(1):11632. PubMed ID: 35804089
[TBL] [Abstract][Full Text] [Related]
7. High expression of Aldolase A predicts poor survival in patients with clear-cell renal cell carcinoma.
Na N; Li H; Xu C; Miao B; Hong L; Huang Z; Jiang Q
Ther Clin Risk Manag; 2017; 13():279-285. PubMed ID: 28280347
[TBL] [Abstract][Full Text] [Related]
8. Fructose-Bisphosphate Aldolase A Regulates Hypoxic Adaptation in Hepatocellular Carcinoma and Involved with Tumor Malignancy.
Li X; Jiang F; Ge Z; Chen B; Yu J; Xin M; Wang J; An L; Wei J; Wu L
Dig Dis Sci; 2019 Nov; 64(11):3215-3227. PubMed ID: 31041640
[TBL] [Abstract][Full Text] [Related]
9. A Comprehensive Prognostic Analysis of POLD1 in Hepatocellular Carcinoma.
Tang H; You T; Sun Z; Bai C
BMC Cancer; 2022 Feb; 22(1):197. PubMed ID: 35189839
[TBL] [Abstract][Full Text] [Related]
10. High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma.
Mu W; Xie Y; Li J; Yan R; Zhang J; Liu Y; Fan Y
World J Surg Oncol; 2022 Jan; 20(1):22. PubMed ID: 35065633
[TBL] [Abstract][Full Text] [Related]
11. Increased CDCA2 Level Was Related to Poor Prognosis in Hepatocellular Carcinoma and Associated With Up-Regulation of Immune Checkpoints.
Tang M; Liao M; Ai X; He G
Front Med (Lausanne); 2021; 8():773724. PubMed ID: 35372372
[TBL] [Abstract][Full Text] [Related]
12. Aldolase A as a prognostic factor and mediator of progression via inducing epithelial-mesenchymal transition in gastric cancer.
Jiang Z; Wang X; Li J; Yang H; Lin X
J Cell Mol Med; 2018 Sep; 22(9):4377-4386. PubMed ID: 29992789
[TBL] [Abstract][Full Text] [Related]
13. Loss-of-Function Genetic Screening Identifies Aldolase A as an Essential Driver for Liver Cancer Cell Growth Under Hypoxia.
Niu Y; Lin Z; Wan A; Sun L; Yan S; Liang H; Zhan S; Chen D; Bu X; Liu P; Chen C; He W; Lu X; Wan G
Hepatology; 2021 Sep; 74(3):1461-1479. PubMed ID: 33813748
[TBL] [Abstract][Full Text] [Related]
14. CPNE1 is a potential prognostic biomarker, associated with immune infiltrates and promotes progression of hepatocellular carcinoma.
Su J; Huang Y; Wang Y; Li R; Deng W; Zhang H; Xiong H
Cancer Cell Int; 2022 Feb; 22(1):67. PubMed ID: 35139863
[TBL] [Abstract][Full Text] [Related]
15. Initial clinical and experimental analyses of ALDOA in gastric cancer, as a novel prognostic biomarker and potential therapeutic target.
Chen L; Wu Z; Guo J; Wang X; Zhao Z; Liang H; Zhang R; Deng J
Clin Exp Med; 2023 Oct; 23(6):2443-2456. PubMed ID: 36422738
[TBL] [Abstract][Full Text] [Related]
16. Prognosis significance and potential association between ALDOA and AKT expression in colorectal cancer.
Xu M; Xi S; Li H; Xia Y; Mei G; Cheng Z
Sci Rep; 2024 Mar; 14(1):6488. PubMed ID: 38499636
[TBL] [Abstract][Full Text] [Related]
17. Identification METTL18 as a Potential Prognosis Biomarker and Associated With Immune Infiltrates in Hepatocellular Carcinoma.
Li TH; Qin C; Zhao BB; Cao HT; Yang XY; Wang YY; Li ZR; Zhou XT; Wang WB
Front Oncol; 2021; 11():665192. PubMed ID: 34123827
[TBL] [Abstract][Full Text] [Related]
18. Aldolase A promotes cell proliferation and cisplatin resistance via the EGFR pathway in gastric cancer.
Gu M; Jiang B; Li H; Zhu D; Jiang Y; Xu W
Am J Transl Res; 2022; 14(9):6586-6595. PubMed ID: 36247245
[TBL] [Abstract][Full Text] [Related]
19. Feedback regulation of ALDOA activates the HIF-1α/MMP9 axis to promote lung cancer progression.
Chang YC; Chan YC; Chang WM; Lin YF; Yang CJ; Su CY; Huang MS; Wu ATH; Hsiao M
Cancer Lett; 2017 Sep; 403():28-36. PubMed ID: 28610954
[TBL] [Abstract][Full Text] [Related]
20. The significance of m6A RNA methylation regulators in predicting the prognosis and clinical course of HBV-related hepatocellular carcinoma.
Fang Q; Chen H
Mol Med; 2020 Jun; 26(1):60. PubMed ID: 32552682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
